New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
November 23, 2016 – The FDA announced the discontinuation of Gilead’s Vitekta (elvitegravir) due to business reasons.
Download PDF
Return to publications
